March 9, 2014
Notes: Hill, Kate M
Walwyn, Rebecca E A
Camidge, Diana C
Meads, David M
Murray, Jenni Y
Farrin, Amanda J
House, Allan O
Randomized Controlled Trial
Research Support, Non-U.S. Gov’t
Trials. 2013 Jul 11;14:212. doi: 10.1186/1745-6215-14-212.
Author Address: Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. firstname.lastname@example.org.
Reference Type: Journal Article
Record Number: 659Author: Hiromasa, S.
Title: [A new strategy of treatment of insomnia in the field of cardiology–potential of ramelteon]
Journal: Nihon Rinsho
Short Title: [A new strategy of treatment of insomnia in the field of cardiology–potential of ramelteon]
Alternate Journal: Nihon rinsho. Japanese journal of clinical medicine
ISSN: 0047-1852 (Print)
Accession Number: 23631192
Keywords: Benzodiazepines/adverse effects/therapeutic use
Sleep Initiation and Maintenance Disorders/complications/*drug therapy
Abstract: Most of patients who visit cardiovascular internal medicine have insomnia. Recently, it becomes evident that insomnia is a risk of developing cardiovascular diseases; therefore, treatment of insomnia is important for treatment of cardiovascular diseases. Because benzodiazepine (BZD) hypnotics, which have been used widely for treatment of insomnia, have several issues in long-term use, this study investigated the potential of ramelteon. The results showed that it is desirable to ask actively about sleep status in routine clinical practice for patients with cardiovascular diseases and to start early treatment with ramelteon for new patients. Moreover, for patients already taken BZD hypnotics, leading them to reduce gradually and discontinue BZD hypnotics by coadministration of ramelteon is preferred.